

27 JANUARY 2021

LGP WINS FRENCH GOVERNMENT TENDER


ASX ANNOUNCEMENT

Highlights:

-  LGP appointed as a primary medicinal cannabis oil manufacturer for national French medicinal cannabis trial in partnership with Intsel Chimos, a leading French pharmaceutical distributor
-  Success of the trial is anticipated to catalyse legalisation of €4 billion French medicinal cannabis market
-  The trial will be the only pathway for the supply of cannabis medicines into France for next two years, and is anticipated to provide LGP with significant first mover advantage in anticipated future French market
-  Tender success demonstrates LGP's status as the leading global cannabis supplier and the merit of LGP's export-led sales strategy

Little Green Pharma Ltd (ASX: LGP, "LGP" or the "Company") is pleased to announce it has been selected as a primary supplier of medicinal cannabis oils for a French national trial of medicinal cannabis in partnership with leading French pharmaceutical distributor, Intsel Chimos ("**Partnership**").

Since 2018, the French National Agency for the Safety of Medicines and Health Products (*L'Agence nationale de sécurité du médicament et des produits de santé*, "**ANSM**") has been developing a *Cahier des Charges* ("**Tender**") for a two-year trial of medicinal cannabis products in the treatment of clinical conditions that are resistant to conventional treatments ("**Trial**"). The Trial is intended to test the efficacy, safety, and quality of medicinal cannabis medicines for the French public and plans to recruit up to 3,000 patients over its duration. If successful, the Trial is anticipated to catalyse the legalisation of medicinal cannabis in France, which is estimated to have a market value of €4 billion at maturity.





Commenting on the Tender win, LGP Managing Director Fleta Solomon said:

"We are very proud of our Partnership's success in the French national tender and see this Tender win as strong evidence of LGP successfully implementing its export-led global sales strategy and demonstrating the benefits of Australian Good Manufacture Practices ("GMP") quality manufacturing in global pharmaceutical markets. We believe the Trial will demonstrate the Partnership's credibility and reliability to the French medical community, giving both companies a significant competitive advantage once medicinal cannabis is legalised in France.

"I'd like to congratulate both Intsel Chimos and LGP teams for their tireless efforts in developing a world-leading bid for the Tender. We trust this marks the beginning of a long and rewarding partnership as we look to grow and cement our reputation amongst French patients and prescribers as a world-class medicinal cannabis supplier."

Under the terms of the Tender:

- global medicinal cannabis producers submitted bids for three categories of formulation, being medicinal cannabis oils, flower and capsules across three cannabinoid ratios, being THC-dominant, THC:CBD balanced, and CBD-dominant cannabis medicines;
- bidders could be awarded a primary supplier role or a backup supplier role; and
- the Trial would be the only pathway for cannabis medicines to be supplied to patients in France during its term.

The Partnership's Tender bid was successful, and the Partnership was awarded:

- primary supplier status for two CBD-dominant oil medicines; and
- backup supplier status for a balanced THC:CBD oil medicine.

Under the terms of the Trial, suppliers will provide the cannabis medicines at their own cost to patients and LGP's distribution partner will comply with all other pharmaceutical obligations under the Tender.

LGP's partner in the Trial, Intsel Chimos, is a French pharmaceutical company and recognised hospital partner, with a track record of more than 50 years in the space and specialising in the importation and distribution of medicines (including narcotics) to French hospitals and dispensaries. Under the Partnership, LGP will manufacture and supply its medicines into France while Intsel Chimos will undertake batch-release, distribution, medical information, and pharmacovigilance obligations.

LGP's role as a primary supplier to the Trial will provide the Company with a significant first mover advantage in the event medicinal cannabis is legalised in France following the Trial. As shown by LGP's own Australian market experience, first-mover advantage is likely to yield significant benefits, including heightened brand-recognition and sales advantages in newly-forming pharmaceutical markets.

LGP's success in the Trial confirms the merit of its strategy in developing a robust, export-led sales strategy, and its status as significant export competitor with other global medicinal cannabis producers who were successful in the Tender, being cannabis majors Tilray, Panaxia and Aurora.





ENDS

BY ORDER OF THE BOARD

A handwritten signature in dark ink, appearing to read "Alistair Warren", is written over a horizontal line.

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma

E: alistair@lgpharma.com.au

M: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma

E: fleta@lgpharma.com.au

M: +41 782 260 200

About Little Green Pharma

Little Green Pharma is a vertically integrated medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has an indoor cultivation facility and manufacturing facility in Western Australia for the production of its own-branded range of GMP-grade medicinal cannabis products.

Little Green Pharma products comply with all required Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp